Antares Pharma (ATRS) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Antares Pharma Reports Fourth Quarter and Full Year 2016 Operating and Financial Results
March 14, 2017 7:00 AM EDT2016 Results Driven by Continued Growth in Product Sales and Significant Progress in Pipeline Programs
 Full Year Revenue of $52.2 Million Increased 14% Versus Prior Year
EWING, N.J., March 14, 2017 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating progress and financial results for the fourth quarter and full year ended December 31, 2016. The Company reported revenue of $14.2 million for the fourth quarter of 2016 and $52.2 million for the full year ended December 31, 2016. Net loss per share... More
